Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaginal Atrophy Clear all
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Vaginal Creams to Reduce Vaginal Erosion in Pessary Users

NCT02316249
View directory record Official record
Conditions
Atrophy of Vagina, Vaginal Ulceration, Vaginitis
Interventions
Estradiol, placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

NCT00803335
View directory record Official record
Conditions
Pelvic Organ Prolapse, Vaginal Atrophy
Interventions
Vaginal conjugated estrogen cream 0.5gm, Vaginal conjugated estrogen cream 1.0gm
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV

NCT02313545
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
IZN-6NVS Cream
Drug
Lead sponsor
Izun Pharma Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
The Bronx, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

NCT00361569
View directory record Official record
Conditions
Menopause
Interventions
DR-2041a, DR-2041b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Jul 22, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

NCT04493333
View directory record Official record
Conditions
Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions
Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer
Drug · Combination Product
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Reproductive Health Survivorship Care Plan

NCT02667626
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Sexual Dysfunction, Fertility, Contraception
Interventions
Reproductive Health Survivorship Care Plan (SCPR), Control
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

NCT01845649
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Jul 22, 2026, 2:06 AM EDT
Not listed Phase 3 Interventional

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

NCT03782480
View directory record Official record
Conditions
Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome, Dyspareunia
Interventions
Intrarosa, Placebos
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Early Phase 1 Interventional Results available

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

NCT01697345
View directory record Official record
Conditions
Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions
Testosterone
Drug
Lead sponsor
Creighton University
Other
Eligibility
50 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

NCT01816139
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
Vehicle, WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
48
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Jul 22, 2026, 2:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors

NCT03257670
View directory record Official record
Conditions
Dyspareunia
Interventions
4% Topical Lidocaine Gel, CO2RE fractional laser therapy
Drug · Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NCT00137371
View directory record Official record
Conditions
Atrophic Vaginitis, Atrophy, Vaginitis
Interventions
PVC (daily for 21 days, 7 days off), PVC (twice weekly)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
480 participants
Timeline
2005 – 2007
U.S. locations
32
States / cities
Tucson, Arizona • Encinitas, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

DHEA Against Vaginal Atrophy - 3-Month Efficacy Study

NCT01256684
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

NCT02670785
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions
Estradiol Vaginal Capsule (EVC), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation

NCT03316950
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
IntraGen RF, DiVA, Placebo (DIVA/IntraGen combined)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Jul 22, 2026, 2:06 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

NCT07526948
View directory record Official record
Conditions
Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions
Vaginal estradiol tablets, Vaginal moisturizer
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 4 Interventional

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

NCT07346287
View directory record Official record
Conditions
Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
Interventions
7-940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Randomized, Controlled Trial With Hybrid Fractional Laser

NCT03647189
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy

NCT01502527
View directory record Official record
Conditions
Vulvo Vaginal Atrophy
Interventions
Femarelle
Dietary Supplement
Lead sponsor
Dr. Lila Nachtigall Rapid Medical Research, New York
Other
Eligibility
40 Years to 85 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Jul 22, 2026, 2:06 AM EDT